Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for MRK, sign up here.
Income Statement
Revenue
$60.1bn
Gross Profit
$44.0bn
Earning before Tax
$1.9bn
Net Income
$365.0m
Net Income Common Shareholders
$365.0m
EPS
0.14
Balance Sheet
Cash
$6.8bn
Debt
$35.1bn
Assets
$106.7bn
Liabilities
$69.0bn
Equity
$37.6bn
Enterprise Value
$302.5bn
Cash Flow Statement
Net Cash from Operations
$13.0bn
Net Cash from Investing
$-14.1bn
Net Cash from Financing
$-4.8bn
Net Cash Flow
$-5.9bn
Free Cash Flow
$9.1bn
Free Cash Flow per Share
$3.60
Metrics
Price to Equity
0.0m
Price to Equity (Damodaran)
0.0m
Price to Book
7.35
Net Margin
0.01
Return on Equity
0.01
Return on Sales
0.05
Get immediate access to 5-years of reference grade data for MRK for free.
Sign upMerck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo''s DXd antibody drug conjugate (ADC) candidates and a collaboration with HiberCell, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Company Info
Industry
Drug Manufacturers - General
Employees
Address
126 East Lincoln Avenue
Rahway, NJ 07065
United States
Phone
908 740 4000
Website
Last Updated
2024-02-19
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.